The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Deutsche Bank initiates Synairgen with 'hold' - target 8 pence
Must have been prompted by something going on?
Holder for a few years, been stung like many others on the P3. I have an expensive hobby investing in crap British biotechs.
Yes this is the news, now showing here...!
"Deutsche Bank initiates Synairgen with 'hold' - target 8 pence"
That is unusual IMO. Why a large IB would cover Synairgen anyway, and especially when there's been zero news for so long...
...Unless they do expect something...
10% drop on the 'news'.
Probably best if we don't get any updates
I will take 8p/Hold from DB rather than Ghia’s recent assessment. There is no update to underpin it, although I agree that there is probably a good reason for its introduction.
I shan’t mention trolls on this forum again, but will continue to filter their messages as before. I now believe that most contributors’ assessment of Sakura7 is correct. S/he initiated the most ludicrous conversation I have seen on a share discussion board.
I hope that today’s DB rating, will soon be followed by a significant update from Synairgen to upwardly reset the company’s ludicrous valuation, currently based on our cash reserve?
GLALTIs.
TP - what's the good reason for the introduction?
Ah, stand down. It's Paul Cuddon who was at Numis, who have been bought out by DB with Paul Cuddon being ported across. So it's not really new coverage.
MrCosts.
Explained by Doc83 below. No real substance to it.
There is no 10% drop either. One small sell, amidst a number of small buys at around the current share price.
The next substantial RNS should be instructive? I have thought the same in the past, so I shall continue to wait, and see what eventually happens?
Highly pathogenic avian influenza H5N1 is certainly starting to look inevitable to have human to human transmission and be the next pandemic. I'm sure many of you follow the same scientists as me like your Brights, Farrar etc and we are seeing very early warning signs.
SNG should be ahead of the game here and be prepping plans in advance ready to fast pivot to H5N1 instead of SARS-COV-2. There is much science showing efficacy of interferon in relation to H5N1 in preventing disease. I think a good question for SNG would be what plans do you already have ready for a H5N1 pivot?
SNG may well get to ride the coat tails of another pandemic but hopefully this time its partnered with a bigger pharma.
Vaccine manufacturers currently working on vaccines for H5N1 and testing companies looking for permission to start creating tests in USA signs are ominous.
Doc83, Deutsch Bank bank concluded Numis takeover 7 months ago. This coverage is new, so I’d assume DB initiated.
Fruits - it has definitely been lodged under Paul Cuddon's name, so while it is under the DB umbrella, it is surely and simply to do with Cuddon's own stocks that he covers, rather than DB as a house having decided to start covering it.
Could of course be wrong. I'll see if I can get in touch with him to confirm if there is a new note on SNG from him.
Thanks Doc83. It could be that it was suspended for that time after Numis acquisition and now it's been rubber stamped as active by DB. Would be good to see if you get a response. 8p forecast, 2p higher than SP, signals some belief that they don't see the company running out of money suddenly or hitting a wall?
8p signals some belief. I've heard it all now.
Cheer up Costas. It could have been 3p. Or 2p. Or 1p.
It shows DN analyst believes it's worth more than you do. Which is odd, seeing as you are in investor?
DB
I've no idea how this all works but if DB took over Numis presumably they HAVE to issue a new broker's note at some point reasonably close to the acquisition. Is this how it works. And in that context is this not - 7 months on - routine and as unremarkable as the number quoted.
If this is entirely wrong please offer a correction.
Not sure what's worse an update from Marsden or a brokers note
I don’t think I’ve ever come across an investor who is equally dismayed by the thought of an update or a positive broker rating. You seem happiest at the thought of the company failing. Such a strange behaviour.
DocDan, the “number” is not an arbitrary one. It is based on is level of analysis of information currently available to the the Analyst.
Oddly, I have taken some encouragement from reading some recent comments here. Why have DB issued this assessment after 7 months?
Presumably, the analyst has worked for DB since the Numis acquisition? It would seem reasonable for him to have reissued an updated Synairgen broker’s note before now?
Has the analyst been prompted recently by the company, or by TFG perhaps, to begin following Synairgen again and to issue an initial assessment to lay down a marker?
This supposes that there are going to be developments ahead, and with them an increase in share price. It has happened with Synairgen before. In early January 2020, the share price was around the current level. Successive developments brought with them significant share price increases culminating in the post P2 moonshot, when the share price rose by 3OX the January 2020 value.
Given a successful outcome to the strategy from September 2023, we could well see success of this kind being repeated? Having brokers on board to monitor the progress and issue advice to investors is an essential part of this process.
I remain somewhat sceptical until we receive news from Synairgen on their strategy's progress. However, today’s note could well be the start of something provided it is followed by positive news on the P2 trials? Until that happens, there is little to discuss. I am guardedly optimistic, and shall continue to check each morning for that elusive RNS.
All IMHO. GLALTIs.
Fruits - let's be honest here, we've not had any positive news for over nearly 2.5 years.
The drug hasn't been trialled on a patient since Nov 2021.
The company won't update us or even talk to us.
Trials to start next month? Really?
I would love to find something positive.
Attending conferences is something this company has done for the last 20 years.
Posting a link about something in America that might happen later this year isn't news either.
Absolutely nothing to get excited about.
DocDan - Numis specialise in UK smaller companies and research. DB very little, so I’m guessing that’s why they wanted them. I’m certain Paul Cuddon hasn’t changed his mind on Synairgen and he’s just said “hold” and quoted the SP when he lodged it. In other words, “nothing to see here”. But I could be wrong. We could do with getting hold of his note… I assume there will be an updated one, even if it’s just with DB’s logo at the top.
I have some of his old notes with contact details on, but I’m guessing they’ll now be obsolete.
DB will not have published a forecast this isn't current. Any previous forecast and rating will have been checked for accuracy against all current available information (peer,market sector - etc) before being published. I don't believe there is any previous note published by Paul Cuddon that pegged a forecast of 8p, unless I missed it? So I think this has to be new, and based on current info.
The last Paul Cuddon Broker Note information I have is dd 17 March 2022 and it was on the Activ-2 update but prior Sprinter results:
"Current share price: 26p
Target price: 220p"
NUMIS / Paul Cuddon – 17 March 2022
Was there a later report published after Sprinter?
There you go.
Post P3 failure - target price 220p
Updated target price 8p with trials to start next month!
The whole saga is a joke.
You're the joke.